$410m Ambit Deal Bolsters Daiichi Sankyo’s Oncology Presence
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's purchase of oncology-focused venture Ambit Biosciences for up to $410 million will bring the major Japanese firm an attractive Phase III asset for acute myeloid leukemia and boost its oncology pipeline.